156 related articles for article (PubMed ID: 33836635)
1. Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?
Badar T; Atallah E
Expert Opin Investig Drugs; 2021 Jun; 30(6):665-673. PubMed ID: 33836635
[TBL] [Abstract][Full Text] [Related]
2. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Garcia-Manero G; Montalban-Bravo G; Berdeja JG; Abaza Y; Jabbour E; Essell J; Lyons RM; Ravandi F; Maris M; Heller B; DeZern AE; Babu S; Wright D; Anz B; Boccia R; Komrokji RS; Kuriakose P; Reeves J; Sekeres MA; Kantarjian HM; Ghalie R; Roboz GJ
Cancer; 2017 May; 123(6):994-1002. PubMed ID: 28094841
[TBL] [Abstract][Full Text] [Related]
3. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
[TBL] [Abstract][Full Text] [Related]
4. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
[No Abstract] [Full Text] [Related]
5. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Kobayashi Y; Munakata W; Ogura M; Uchida T; Taniwaki M; Kobayashi T; Shimada F; Yonemura M; Matsuoka F; Tajima T; Yakushijin K; Minami H
Int J Hematol; 2018 Jan; 107(1):83-91. PubMed ID: 28905323
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
Ball B; Zeidan A; Gore SD; Prebet T
Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
[TBL] [Abstract][Full Text] [Related]
7. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
9. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.
Bouchla A; Thomopoulos TP; Papageorgiou SG; Apostolopoulou C; Loucari C; Mpazani E; Pappa V
Epigenomics; 2021 Jul; 13(14):1129-1143. PubMed ID: 34291653
[TBL] [Abstract][Full Text] [Related]
10. Treatment of higher-risk myelodysplastic syndrome.
Garcia-Manero G
Semin Oncol; 2011 Oct; 38(5):673-81. PubMed ID: 21943674
[TBL] [Abstract][Full Text] [Related]
11. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
12. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Merkel DG; Nagler A
Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
[TBL] [Abstract][Full Text] [Related]
13. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Ishikawa T
Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
17. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
Platzbecker U; Germing U
Leukemia; 2013 Sep; 27(9):1813-9. PubMed ID: 23644421
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
Yalniz FF; Berdeja JG; Maris MB; Lyons RM; Reeves JA; Essell JH; Patel P; Sekeres M; Hughes A; Mappa S; Garcia-Manero G
Br J Haematol; 2020 Feb; 188(3):404-412. PubMed ID: 31468521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
